Dr. Choyke on Which Patients Benefit From Active Surveillance in Prostate Cancer

Peter Choyke, MD, FACR
Published: Thursday, Aug 03, 2017



Peter Choyke, MD, FACR, chief of Molecular Imagine Program, National Cancer Institute, discusses which patients with prostate cancer benefit from active surveillance.

There is very good long-term safety data for patients who are appropriately selected for active surveillance, says Choyke.

The patients who benefit from active surveillance have very low-risk cancer with a negative MRI.
 
SELECTED
LANGUAGE


Peter Choyke, MD, FACR, chief of Molecular Imagine Program, National Cancer Institute, discusses which patients with prostate cancer benefit from active surveillance.

There is very good long-term safety data for patients who are appropriately selected for active surveillance, says Choyke.

The patients who benefit from active surveillance have very low-risk cancer with a negative MRI.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x